IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Rating of “Moderate Buy” from Brokerages

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $751.00.

A number of research analysts have issued reports on IDXX shares. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th.

Institutional Trading of IDEXX Laboratories

A number of hedge funds have recently modified their holdings of IDXX. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $26,000. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $26,000. Park Place Capital Corp bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $29,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $36,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.6%

Shares of IDEXX Laboratories stock opened at $551.50 on Friday. IDEXX Laboratories has a 1 year low of $506.91 and a 1 year high of $769.98. The firm has a market cap of $43.50 billion, a PE ratio of 40.61, a PEG ratio of 3.04 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The company has a 50 day simple moving average of $558.79 and a two-hundred day simple moving average of $614.78.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period in the previous year, the business posted $2.91 EPS. The business’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts expect that IDEXX Laboratories will post 14.68 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.